Cell / animal study· 2017
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.
Cell
Back to all molecules
PreclinicalNot FDA-approved
FOXO4-DRI
D-retro-inverso research peptide
Also indexed as: FOXO4 D-Retro-Inverso peptide
What this evidence does not tell us
The cited research includes cells and mice. Restored tissue markers in mice are not proof of human rejuvenation.
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
5 glossary terms used in this profile
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
5 glossary terms used in this profile
Select a word to see its meaning. You can keep more than one definition open.
Definitions explain the words—not whether a molecule works or is safe. Research education only, not medical advice.
Overview
FOXO4-DRI is a laboratory-designed D-retro-inverso peptide studied as a senolytic candidate. Its structure and experimental purpose distinguish it from a naturally occurring FOXO4 protein.
Mechanism of action
FOXO4 / p53 / senescence
Designed to disrupt FOXO4–p53 interactions, promoting apoptosis in senescent-cell models. Selectivity in experimental models does not establish human safety.
A biological pathway describes a proposed or observed interaction—not necessarily a demonstrated health outcome.
Decode the terminology in our glossaryPut the research in context
Simplified educational maps—not a treatment pathway or a prediction of benefit.
Scientific evidence
How strong is the evidence?
Early lab & animal research
- Limited evidence
- Early researchCurrent category
- Human research
- Human outcomes
Most support comes from cells or animals. These studies help form questions, but do not prove a treatment works in people.
For this research: The cited research includes cells and mice. Restored tissue markers in mice are not proof of human rejuvenation.
An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.
Cell studies
The linked study disrupts FOXO4–p53 interactions in senescent cells to investigate apoptosis.
Animal experiments
Mouse studies examined tissue-function measures after senescent-cell targeting. No human lifespan conclusion follows.
Human observational studies
Associations, biomarker studies and anecdotes cannot establish treatment causality; no observational result is used here to infer clinical effectiveness.
Human clinical trials
Reliable, independently replicated human outcome evidence is not established by the selected sources in this edition.
Regulatory evidence
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Potential research applications
Selective removal of senescent cells in laboratory models.
These describe scientific questions, not prescribing recommendations. A research grouping does not establish combination safety or clinical effectiveness.
Explore research by health goalSafety considerations
Human toxicology is not established. Manipulating apoptosis and senescence may affect normal repair; selectivity and long-term effects require study.
This is not an exhaustive safety or contraindication list. An absence of reported harm is not proof of safety. Pregnancy, breastfeeding, cancer history, endocrine disease and concurrent medicines can materially change risk. Unregulated preparations add identity, contamination and sterility risks.
Regulatory status · United States
Not FDA-approved
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Regulatory status and evidence strength are different. A nomination for compounding, a clinical-trial registration or a “research use only” label is not approval. International rules vary; consult the current regulator and product label.
Selected literature & source transparency
Matched bibliographic records confirm a publication’s identity, not the validity of every claim. Selected sources are not a systematic literature review.
Continue your own source search
These open search results, not additional verified citations. Trial registration is not evidence that a treatment works.
Three questions worth bringing to your clinician
- Which human outcomes—not just biomarkers—support this claim?
- What established options address my actual health concern?
- What do my medical history and current medicines change about the risks?
Beyond the library
Turn better questions into a thoughtful conversation.
Explore our broader health optimization approach. A library entry does not mean a molecule is offered, prescribed, or appropriate for you.
Request an Optimization Consultation
Continue to our existing activation & intake page.